

PROFILE

EMBARGOED: THURSDAY, MARCH 20, 2025

Dr Paul Reddell, B.Sc. (Hons.) PhD FAICD

Executive Director, Chief Scientific Officer and Co-Founder, QBiotics Group, BRISBANE

Dr Paul Reddell is the Executive Director, Chief Scientific Officer (CSO) and Co-Founder of QBiotics Group Limited (QBiotics) — an unlisted, public, Australian clinical stage life sciences company specialising in the discovery and development of novel cell signalling small molecules.

Paul brings extensive scientific knowledge and practical experience in leadership, resourcing, management and commercialisation of complex multi-institutional research and development projects, to his CSO role at QBiotics.

He is the co-founder of EcoBiotics and QBiotics, and has been CSO of both companies since their inception.

Prior to co-founding EcoBiotics in 2000, Paul gained

an international reputation for his scientific expertise in tropical forest ecology and management. During that time, he served as a Senior Principal Research Scientist and Program Leader at CSIRO's Tropical Forest Research Centre between 1993–2003, and later as Principal Plant Ecologist for an environmental consulting business in the Rio Tinto group of companies.

Paul holds a PhD in Forest Ecology and a Bachelor of Science (1A Honours) in Plant Nutrition from the University of Western Australia (UWA). He has been a Fellow of the Australian Institute of Company Directors (AICD) since 2007.

He is a Director of QBiotics Group and its wholly-owned subsidiary companies, QBiotics Pty Ltd, EcoBiotics Pty Ltd, QBiotics Netherlands B.V. and QBiotics UK Limited.

"For 25 years, QBiotics has been driven by the extraordinary potential of nature to inspire breakthrough medical treatments. Our EcoLogic™ platform allows us to harness biologically active molecules from plants, leading to innovative treatments in oncology and wound healing," said Dr Reddell.

"Nature remains an untapped reservoir of powerful compounds, and through our rigorous scientific approach, we are transforming these natural discoveries into real-world solutions.

"As we celebrate this milestone, we remain committed to pushing the boundaries of pharmaceutical innovation, unlocking nature's secrets to improve human and animal health," Dr Reddell said.



To coordinate an interview with Dr Paul Reddell, please contact Kirsten Bruce, VIVA! Communications:

M +61 (0)401 717 566

T +61 (0)2 9968 3741

E <u>kirstenbruce@vivacommunications.com.au</u>